Cowen's Line in the Sand
Executive SummaryCowen's Dan LeMaitre, a leading device analyst, dropped coverage of Boston Scientific claiming that the company wasn't providing sufficient information for accurate valuations. The dispute calls into question an investor relations strategy one executive calls "seriously flawed."
You may also be interested in...
The company has come a long way since gene therapy flop Glybera, and claims best-in-class status for viral vector.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.